NSTEMI Involves Partial Occlusion with Troponin Rise. Risk Stratification Determines Whether Catheterization Is Urgent.

What It Is

NSTEMI (non-ST-elevation myocardial infarction) is an acute myocardial infarction in which the ECG does not show ST-segment elevation, but troponin is raised above the 99th percentile of a normal reference population, indicating myocardial necrosis.

The pathophysiology is similar to STEMI: plaque rupture or erosion triggers coronary thrombus formation. The critical difference is that in NSTEMI, the thrombus does not completely occlude the artery (or the artery is transiently occluded but spontaneously reperfuses). Blood still flows through the artery, but the residual flow is inadequate to meet myocardial oxygen demand. The result is subendocardial ischemia and necrosis (the innermost layer of the myocardium, most vulnerable to ischemia because it is farthest from the epicardial coronary supply).

Because the ischemia is subendocardial rather than transmural, the ECG shows ST depression (subendocardial ischemia pattern) rather than ST elevation. This is the ECG signature of NSTEMI: the absence of ST elevation defines it, not its absence of danger.

NSTEMI and unstable angina together form the category of non-ST-elevation acute coronary syndrome (NSTE-ACS). The distinction between NSTEMI and unstable angina is simply troponin elevation: NSTEMI has it, unstable angina does not.

NSTEMI is more common than STEMI. In the United States, approximately 400,000 to 450,000 NSTEMIs are hospitalized annually, compared to approximately 300,000 STEMIs. Despite this higher prevalence, NSTEMI has historically been treated with less urgency, which has led to excess mortality that recent guideline emphasis has worked to address.

The Mechanism

Why the Thrombus Is Partial

The difference between NSTEMI and STEMI often comes down to the completeness of coronary occlusion. In STEMI, the thrombus is complete: TIMI 0 (no flow). In NSTEMI, the thrombus is partial: TIMI 1, 2, or 3 (some flow). The determinants of whether a ruptured plaque generates a complete versus partial occlusion include:

• Plaque burden: A larger lipid core generates a larger thrombogenic stimulus.
• Collateral circulation: Rich collateral flow from other coronary branches can maintain distal perfusion even in near-complete occlusion.
• Thrombus composition: Platelet-rich (white) thrombi are more easily dissolved by endogenous thrombolysis than fibrin-rich (red) thrombi, which may produce shorter duration occlusions.
• Dynamic spasm: Some NSTEMIs involve coronary vasospasm superimposed on a partially occluding thrombus, producing transient complete occlusion that self-resolves.

The Subendocardial Vulnerability

The subendocardium is uniquely vulnerable to ischemia for anatomical and physiological reasons. Coronary blood flow occurs predominantly during diastole, when the ventricular wall is relaxed. The subendocardium, deep within the ventricular wall, has the longest path from the epicardial coronary vessel. Intramyocardial pressure is highest at the endocardium during systole, which compresses subendocardial vessels during each contraction. For these reasons, any reduction in coronary supply or increase in demand preferentially affects the subendocardium first.

The wavefront of necrosis in NSTEMI runs from endocardium outward. If the ischemia is mild or brief, only the subendocardial layers die. If more severe or prolonged (as when a partial occlusion becomes nearly complete), the necrosis extends toward the epicardium, approaching the transmural pattern of STEMI.

Type 2 NSTEMI: Demand Ischemia

Not all NSTEMIs arise from plaque rupture (Type 1 MI). Type 2 MI occurs when an underlying supply-demand mismatch, without a primary coronary event, causes myocardial ischemia severe enough to produce troponin elevation. Common causes:

• Sepsis with hypotension (severe reduction in coronary perfusion pressure)
• Rapid atrial fibrillation with very high heart rate (shortened diastolic filling time starves the subendocardium)
• Severe hypertensive emergency (excessive afterload demand)
• Severe anemia (reduced oxygen delivery)
• Aortic stenosis with acute hemodynamic stress

Type 2 MI has different management than Type 1 NSTEMI: the primary treatment is addressing the precipitating condition, not coronary revascularization (though severe CAD that precipitated the Type 2 MI may eventually need treatment). Distinguishing Type 1 from Type 2 MI requires careful clinical assessment and often coronary angiography.

How We Diagnose

High-Sensitivity Troponin: The Diagnostic Revolution

The introduction of high-sensitivity troponin (hs-Tn) assays has changed the diagnosis of NSTEMI. Conventional troponin assays were typically positive 4 to 6 hours after the onset of ischemia. hs-Tn assays (hs-TnI or hs-TnT) are positive in 80 to 90 percent of NSTEMIs within 1 to 2 hours of presentation, with very low concentrations measurable that are undetectable by conventional assays.

The 0/1-hour algorithm (ESC 2020): measure hs-Tn at presentation and at 1 hour. If both measurements are very low (below rule-out values), the negative predictive value for NSTEMI exceeds 99 percent and the patient can be considered for early discharge. If the initial hs-Tn is raised or the 1-hour rise is above the defined delta threshold, NSTEMI is confirmed. This algorithm has reduced unnecessary hospital admissions while safely accelerating discharge in low-risk patients.

The caveat: hs-Tn elevation is not specific to myocardial infarction. Heart failure, myocarditis, pulmonary embolism, renal failure, and even sepsis can raise hs-Tn. The diagnosis of NSTEMI requires raised hs-Tn in the context of a compatible clinical presentation.

Risk Stratification: TIMI and GRACE Scores

NSTEMI is not a homogeneous condition. Risk ranges from the 63-year-old woman with deep ST depression and rising troponin (high risk; early invasive strategy warranted) to the 45-year-old man with mildly raised troponin, a single abnormal reading, no ECG changes, and low CAD risk factors (low risk; may not require urgent angiography).

TIMI Risk Score (0 to 7): Assigns points for age over 65, at least three CAD risk factors, known CAD (stenosis over 50 percent), ST deviation, at least two anginal events in the prior 24 hours, aspirin use in the prior 7 days (a paradox that indicates severe underlying disease), and raised cardiac markers. Score 0-2: low risk; 3-4: intermediate; 5-7: high risk.

GRACE Score: Uses continuous variables (age, heart rate, systolic BP, Killip class, creatinine, cardiac arrest, ST deviation, initial cardiac biomarker elevation) to provide a more granular probability estimate of in-hospital and 6-month mortality. The GRACE score is preferred in many guidelines for guiding the urgency of invasive strategy.

ECG in NSTEMI

ST depression. Horizontal or downsloping ST depression is the most specific ECG finding in NSTEMI. Upsloping ST depression is less specific. The depth and number of leads involved correlate with the extent of ischemia.

T-wave inversions. Deep, symmetrical T-wave inversions (Wellens pattern) in the anterior precordial leads are a high-risk finding indicating critical LAD stenosis, even in the absence of troponin elevation. These patients have unstable angina or early NSTEMI and must be admitted for urgent angiography.

Transient ST elevation. Some NSTEMIs present with transient ST elevation that has normalized by the time of ECG recording, leaving residual ST depression or T-wave inversions. The history of transient ST elevation with chest pain followed by spontaneous resolution is important and changes risk classification toward high risk.

The Evidence

FRISC-II: Early Invasive vs. Conservative Strategy

The FRISC-II trial enrolled 2,457 patients with NSTE-ACS and randomized them to early invasive strategy (angiography within 7 days) versus conservative strategy (medical therapy with angiography only if refractory symptoms or positive stress test). Early invasive strategy significantly reduced death or MI at 6 months (9.4 percent versus 12.1 percent; RR 0.78; NNT 37) 5 / Solid 07252-1).

TACTICS-TIMI 18: Confirming the Invasive Benefit

TACTICS-TIMI 18 randomized 2,220 patients with NSTE-ACS to early invasive (angiography within 4 to 48 hours) versus conservative strategy. Early invasive strategy reduced the composite of death, MI, or rehospitalization for ACS at 6 months (15.9 percent versus 19.4 percent; OR 0.78; p=0.025) 5 / Solid . Importantly, the benefit was concentrated in troponin-positive patients: those with normal troponin had no benefit from early invasive strategy, reinforcing the principle that biomarker status should guide strategy.

ICTUS: When Conservative Management is Equivalent

Not all NSTEMI trials favor the invasive strategy. ICTUS enrolled 1,200 patients with raised troponin and either ST deviation or coronary artery disease history, and randomized them to early invasive versus selective invasive (conservative) management. At one year, there was no significant difference in death, MI, or rehospitalization between strategies 5 / Solid . The ICTUS trial population had high rates of revascularization in the conservative arm (47 percent crossed over to revascularization) and lower-risk characteristics than the FRISC-II and TACTICS populations.

The synthesis: for high-risk NSTEMI (deep ST depression, significantly raised troponin, GRACE score greater than 140, hemodynamic instability), early invasive strategy within 24 hours is strongly supported. For lower-risk NSTEMI, a selective invasive approach (conservative strategy with objective ischemia testing and angiography if positive) may be appropriate.

TIMACS: Timing of Invasive Strategy

TIMACS randomized 3,031 patients with NSTE-ACS to routine early intervention (angiography within 24 hours) versus delayed intervention (angiography after 36 or more hours). There was no significant difference in the primary endpoint (death, MI, or stroke at 6 months) overall. However, in the prespecified high-risk subgroup (GRACE score above 140), early intervention significantly reduced the primary endpoint (13.9 percent versus 21.0 percent; HR 0.65; p=0.003) 5 / Solid .

This trial established the differentiated timing recommendation: very high-risk NSTEMI (cardiogenic shock, refractory chest pain despite medical therapy, life-threatening ventricular arrhythmia) warrants immediate angiography (less than 2 hours, equivalent to STEMI management). High-risk NSTEMI (GRACE greater than 140) warrants early angiography within 24 hours. Intermediate-risk NSTEMI warrants angiography within 24 to 72 hours.

ACUITY: Anticoagulation in NSTE-ACS

ACUITY randomized 13,819 patients with moderate to high-risk NSTE-ACS undergoing invasive management to three anticoagulation strategies: unfractionated heparin plus GP IIb/IIIa inhibitor, bivalirudin plus GP IIb/IIIa inhibitor, or bivalirudin alone. Bivalirudin alone was non-inferior to heparin plus GP IIb/IIIa for ischemic outcomes and significantly reduced major bleeding (3.0 percent versus 5.7 percent; RR 0.53; p<0.001) 5 / Solid .

The ACUITY result, combined with HORIZONS-AMI, established bivalirudin as a standard anticoagulation option for ACS patients undergoing PCI, particularly when bleeding risk is raised.

Dual Antiplatelet Therapy Duration

The appropriate duration of DAPT after PCI for NSTEMI balances the risk of stent thrombosis (reduced by longer DAPT) against the risk of bleeding (increased by longer DAPT). The standard is 12 months of P2Y12 inhibitor plus aspirin after drug-eluting stent placement in ACS. The DAPT trial showed that extending DAPT beyond 12 months reduces stent thrombosis and MI but increases major bleeding and non-cardiovascular mortality 5 / Solid . The decision to extend beyond 12 months is individualized based on ischemic versus bleeding risk.

The Patient Experience

The Ambiguity of NSTEMI

STEMI generates an immediate, system-wide response: the cath lab activates, teams converge, the patient is whisked to the procedure room within the hour. NSTEMI, despite being a heart attack, generates a more ambiguous experience: the patient is admitted, started on medications, and told they need a procedure, probably tomorrow.

This timing difference is medically justified: NSTEMI is not a complete coronary occlusion and does not have the same minute-by-minute myocardial death rate as STEMI. But the patient’s experience of that ambiguity is often distressing. “You told me I’m having a heart attack, but you’re waiting until tomorrow?” is a reasonable question that requires a clear, honest answer.

The answer is: in most NSTEMI cases, the artery is still partially open. The medications started (aspirin, heparin, P2Y12 inhibitor) are treating the acute thrombotic process. The risk is real but not as minute-dependent as STEMI. For high-risk features (ongoing chest pain, deep ST depression, hemodynamic instability), the timeline accelerates to immediate angiography.

Sex Differences in NSTEMI

NSTEMI disproportionately represents the female heart attack presentation. Women with NSTEMI are more frequently misdiagnosed, receive less aggressive pharmacological therapy, are less frequently referred for cardiac catheterization, and have higher rates of complications and mortality when treatment is equivalent to men’s 5 / Solid .

Several factors contribute:

• Women more often present with atypical symptoms (nausea, fatigue, back pain, jaw pain) without classic chest pressure
• Women more often have non-obstructive coronary artery disease (MINOCA: myocardial infarction with non-obstructive coronary arteries), where angiography shows no culprit lesion. MINOCA is found in 5 to 15 percent of women presenting with NSTEMI, compared to 1 to 3 percent of men (see MINOCA in men for the male-specific mechanisms and workup)
• Implicit bias in clinician recognition of female cardiac presentations has been documented in multiple studies

For women with NSTEMI-equivalent presentations: insistence on the complete diagnostic workup (serial troponin, echocardiography, and angiography for high-risk features) is not optional. The “young woman with atypical symptoms and normal ECG” who has been discharged from the emergency department with a diagnosis of anxiety or musculoskeletal pain is a documented and recurring tragedy.

MINOCA: When the Arteries Are Open But It Is Still an MI

Approximately 5 to 15 percent of patients with a clinical picture of NSTEMI who go to coronary angiography have no culprit obstructive lesion (less than 50 percent stenosis in any vessel). This is MINOCA.

MINOCA is not a “normal” result. It is an MI with a different mechanism than atherosclerotic plaque rupture. The differential diagnosis includes: coronary vasospasm (Prinzmetal’s angina), coronary microvascular disease, spontaneous coronary artery dissection (SCAD), myocarditis (which can mimic ACS), and Takotsubo cardiomyopathy.

The diagnostic workup of MINOCA includes cardiac MRI (to identify myocarditis or Takotsubo), provocative vasospasm testing (intracoronary acetylcholine), and optical coherence tomography (OCT) of the coronary arteries (to identify plaque erosion or subtle dissection not visible by angiography).

SCAD (spontaneous coronary artery dissection) deserves special mention because it occurs predominantly in young women (median age 42), often in the peripartum period or in women with fibromuscular dysplasia, and is missed unless OCT or intravascular imaging is performed. The management of SCAD is non-interventional in most cases (conservative management with anticoagulation and beta-blocker), the exact opposite of the stenting approach for atherosclerotic NSTEMI.

Decisions and Trade-Offs

Timing of Angiography: The Stratified Approach

The most important management decision in NSTEMI is when to perform coronary angiography. The tiered approach based on risk:

Very high risk (immediate, less than 2 hours): Hemodynamic instability, refractory chest pain despite guideline-directed medical therapy, life-threatening arrhythmia, mechanical complications of MI, acute heart failure.

High risk (early, within 24 hours): GRACE risk score above 140, dynamic ST changes, significant troponin rise, positive cardiac biomarkers.

Intermediate risk (within 24 to 72 hours): GRACE score 109 to 140, diabetes, impaired renal function (eGFR below 60), left ventricular EF below 40 percent, prior coronary revascularization.

Low risk: None of the above. Stress testing may substitute for angiography in initial evaluation.

This stratification is the core of the 2020 ESC NSTEMI guidelines and differs from the “activate the cath lab immediately” approach of STEMI.

Conservative vs. Invasive: Patient Preference Matters

The trials comparing invasive versus conservative strategy showed modest net benefit for the invasive approach in high-risk patients. In the ISCHEMIA trial (which enrolled stable ischemic heart disease, not NSTEMI, but provides relevant context), routine angiography and revascularization did not reduce death or MI compared to standard medical therapy in patients with stable moderate to severe ischemia 5 / Solid . The ISCHEMIA result pertains to stable disease; for NSTEMI, the active ischemic process and rising troponin represent a different and more urgent situation. But it contextualizes the discussion: invasive management in NSTEMI is about preventing recurrent events and defining anatomy, not always about mortality reduction.

Some patients, after informed discussion, prefer a conservative approach. This is a legitimate choice for low-risk NSTEMI in patients with multiple comorbidities or strong preference against invasive procedures. The cardiologist’s role is to provide the risk-benefit framework, not to override patient autonomy.

Bleeding Risk and the “Academic Equipoise” of DAPT Duration

After PCI for NSTEMI, the 12-month DAPT recommendation sometimes conflicts with individual patient circumstances: the patient who needs elective surgery at 6 months, the patient with prior gastrointestinal bleeding, the patient on chronic anticoagulation for atrial fibrillation (triple therapy with aspirin, P2Y12 inhibitor, and anticoagulant carries substantial bleeding risk).

The WOEST trial showed that, in patients requiring both PCI and oral anticoagulation, clopidogrel plus oral anticoagulant (without aspirin) reduced bleeding without increasing MI or stent thrombosis 4 / Promising 62177-1). This has been extended and confirmed in larger trials using newer DOACs. Triple therapy (aspirin + P2Y12 inhibitor + anticoagulant) should be minimized to the shortest clinically necessary duration.

Clinical Synthesis

NSTEMI is the heart attack that disguises itself. It does not produce the sudden crushing chest pain of a classic anterior STEMI. It produces three days of “indigestion” in a 63-year-old woman who has never been told her LDL-C is 160 mg/dL, her blood pressure is 148/90, and her ten-year cardiovascular risk is 22 percent.

This clinical framework addresses NSTEMI at every prevention layer.

Primary prevention. A structured cardiovascular assessment quantifies cardiovascular risk in every patient who engages with the program. For a 63-year-old woman with hypertension and hyperlipidemia and a family history of coronary artery disease, a structured cardiovascular assessment generates a specific intervention plan: LDL-C to below 70 mg/dL with high-intensity statin and possibly ezetimibe or a PCSK9 inhibitor; blood pressure to below 130/80; consideration of aspirin (the risk-benefit calculation is patient-specific and guideline-nuanced); smoking cessation if applicable; physical activity goal.

Secondary prevention after NSTEMI. The post-NSTEMI patient needs the same structured program as the post-STEMI patient: DAPT adherence confirmation, statin dose titration with LDL-C recheck at 6 weeks, blood pressure management, cardiac rehabilitation enrollment, depression screening, and follow-up echocardiography.

The sex-disparity gap. Women are underserved in NSTEMI care. This program explicitly names this gap: women presenting with atypical cardiac symptoms deserve the same systematic risk evaluation as men with classic presentations. An older woman with unexplained nausea, back pain, and new fatigue gets the same a structured cardiovascular assessment cardiovascular risk profile as the man with crushing chest pain and diaphoresis.

MINOCA investigation coordination. The subset of NSTEMI patients with non-obstructive coronaries requires a workup that spans echocardiography, cardiac MRI, vasospasm testing, and intravascular imaging. This is not straightforwardly coordinated in most clinical systems. A cardiologist-led preventive program provides the coordination infrastructure to ensure this workup happens and that the results drive a specific management plan.

See also: STEMI for the ST-elevation counterpart; Unstable Angina for the pre-infarction syndrome without troponin elevation.

The NSTEMI Spectrum: Definitional Precision

Type 1 Versus Type 2 MI: The Universal Definition Framework

The 2018 Fourth Universal Definition of Myocardial Infarction introduced a clinically important categorical distinction that changes both management and prognosis:

Type 1 MI (spontaneous MI): Plaque rupture, erosion, or calcified nodule causing coronary thrombus and myocardial ischemia. This is the classic atherosclerosis-driven ACS. NSTEMI from Type 1 MI is the entity addressed by FRISC-II, TACTICS-TIMI 18, and TIMACS.

Type 2 MI (supply-demand mismatch MI): Myocardial ischemia from a cause other than primary coronary thrombosis. The supply-demand mismatch can be caused by: coronary artery spasm (Prinzmetal angina), coronary artery dissection, tachyarrhythmia (rapid atrial fibrillation), severe anemia (hemoglobin below 7 g/dL with compromised coronary flow reserve), hypertensive emergency, septic shock (catecholamine-mediated coronary spasm and oxygen demand increase), and perioperative ischemia.

Why this distinction matters: Type 2 NSTEMI is not treated with coronary angiography and stenting. The underlying cause must be treated. A patient who develops troponin elevation during a bout of rapid atrial fibrillation at 180 beats per minute does not need emergency cardiac catheterization; the patient needs rate control. A patient who develops troponin elevation during septic shock requires hemodynamic resuscitation and antibiotic therapy, not urgent angiography. Performing coronary angiography in Type 2 MI (finding non-obstructive or no significant disease) wastes resources, exposes the patient to contrast and vascular access risk, and does not treat the underlying condition.

Type 2 MI is significantly underrecognized in clinical practice. Studies suggest it represents 25 to 40 percent of all troponin elevations meeting MI criteria in hospitalized patients 4 / Promising . The diagnostic investment in distinguishing Type 1 from Type 2 MI is worthwhile because the management is fundamentally different.

MINOCA: Myocardial Infarction with Non-Obstructive Coronary Arteries

MINOCA represents approximately 5 to 10 percent of NSTEMI presentations. The patient has clinical NSTEMI (symptoms, troponin elevation, ECG changes) but coronary angiography shows no obstructive disease (less than 50 percent stenosis in any major vessel). MINOCA has multiple etiologies that require specific workup:

Coronary microvascular dysfunction: The microvasculature spasms or fails to dilate appropriately, producing ischemia despite patent epicardial vessels. Documented by acetylcholine provocative testing at the time of coronary angiography or by coronary flow reserve measurement. More common in women.

Coronary vasospasm (Prinzmetal angina): Epicardial coronary artery spasm produces transient complete or near-complete occlusion. Often nocturnal, often at rest, with rapid spontaneous resolution. ECG shows transient ST elevation during the episode. Associated with smoking, cocaine, ergotamine, and rarely with inflammatory conditions. Treated with calcium channel blockers and long-acting nitrates.

Plaque erosion with spontaneous thrombolysis: A thrombus forms on an eroded plaque (without rupture) and lyses before angiography is performed, leaving the coronary artery looking normal at the time of catheterization. This is the proposed mechanism for a substantial proportion of MINOCA cases in young women and smokers.

Spontaneous Coronary Artery Dissection (SCAD): Intramural hematoma in the coronary artery wall, not from atherosclerotic plaque, causing luminal obstruction. SCAD accounts for approximately 30 percent of MINOCA cases in women under 50. Detection requires careful angiographic technique: the dissection appears as a long, smooth stenosis, sometimes with a “staining” pattern of dye in the false lumen, or on intracoronary OCT as an intramural hematoma compressing the true lumen from outside.

The MINOCA workup after angiography should include: cardiac MRI (to assess for myocarditis, myocardial fibrosis pattern suggestive of prior ischemia, and late gadolinium enhancement distribution); Holter monitor (to detect nocturnal arrhythmia); transthoracic echocardiogram (to assess for LVEF and regional wall motion abnormality); thrombophilia panel if age below 50; and consideration of coronary vasoreactivity testing at a center with that capability 5 / Solid .

Mechanism Extended

The Culprit Lesion in NSTEMI: Partial Versus Complete Occlusion

The fundamental anatomical difference between STEMI and NSTEMI is the degree of coronary obstruction. In STEMI, the vessel is completely occluded: zero antegrade flow, maximal ischemia, immediate necrosis in the territory at risk. In NSTEMI, the vessel is partially occluded: reduced but not absent antegrade flow, ischemia in the subendocardium, necrosis limited to the zone of most severe ischemia.

The partial occlusion in NSTEMI may result from:

• An incompletely occlusive thrombus (the platelet-fibrin thrombus is partially lysed by the endogenous fibrinolytic system before complete occlusion develops)
• An angiographically moderate stenosis that has become physiologically flow-limiting due to vasospasm superimposed on a fixed stenosis
• A subtotal stenosis that does produce TIMI 1 to 2 flow (very reduced but not zero)

The downstream ischemia pattern in NSTEMI is subendocardial: the innermost myocardium receives blood last from the coronary distribution, experiences ischemia first with even moderate supply reduction, and produces the characteristic ST-depression and T-wave inversion (rather than ST elevation) of the subendocardial injury current.

Importantly, some NSTEMI presentations involve a very small terminal branch occlusion (diagonal, obtuse marginal, or posterolateral branch), where the territory at risk is small, complete occlusion produces an NSTEMI rather than a STEMI pattern (because the ECG ST elevation threshold requires a larger territory), and the clinical presentation is a modest troponin elevation with minimal symptoms. This is an important category not to under-treat: even small territory MI carries adverse remodeling risk if the vessel is not opened.

Thrombus Evolution in the Non-STEMI Setting

The thrombus in NSTEMI differs in its composition from STEMI thrombus. NSTEMI thrombus tends to be more platelet-rich (white thrombus) and less fibrin-rich than STEMI thrombus. This compositional difference partially explains why NSTEMI thrombus does not respond as well to fibrinolytic therapy (which dissolves fibrin), and why platelet inhibition with P2Y12 antagonists and GPIIb/IIIa inhibitors is so important in NSTEMI management.

The thrombus composition also evolves over time: as the thrombus ages from hours to days, it becomes more fibrin-organized and less platelet-dominated. This has implications for the timing of catheterization: an NSTEMI patient taken to the catheterization laboratory at 2 hours may have a soft, friable, platelet-rich thrombus that is susceptible to distal embolization during percutaneous manipulation; a patient catheterized at 24 hours may have a more organized thrombus. Pre-treatment with antithrombotic therapy (heparin, P2Y12 inhibitor) for 12 to 24 hours before catheterization may reduce thrombus burden and improve procedural outcomes.

Diagnosis Extended

High-Sensitivity Troponin Protocols

The introduction of high-sensitivity troponin (hs-cTnI and hs-cTnT) assays has changed NSTEMI diagnosis. hs-cTn assays can detect troponin concentrations 10 to 100-fold lower than conventional assays, enabling earlier detection of myocardial injury.

The 0/1h algorithm (European Society of Cardiology): if hs-cTn is below the limit of detection at presentation AND remains below a very low threshold at 1 hour, and clinical probability of ACS is low, the patient can be safely discharged with very low short-term MACE risk (missed NSTEMI rate below 1 percent). If hs-cTn is above the 99th percentile at presentation OR rises by more than 5 ng/L at 1 hour, NSTEMI is confirmed and management proceeds 5 / Solid . The 0/2h algorithm (NICE in the UK, using a different assay-specific threshold) has also been validated.

This replaced the traditional 6-hour troponin rule-out strategy with a 1-to-2-hour algorithm that dramatically reduces emergency department stay for the majority of patients who are ultimately ruled out.

The important caveat: hs-cTn is more sensitive but not more specific. Troponin elevations occur in a wide range of conditions: heart failure, myocarditis, pulmonary embolism, renal failure, sepsis, and critically ill patients with any cause of hemodynamic stress. The clinical context must guide interpretation; an raised hs-cTn in isolation does not mean NSTEMI.

Coronary CTA as Triage Tool

Coronary CT angiography (CCTA) provides non-invasive visualization of coronary anatomy and is increasingly used in the triage of patients with chest pain and intermediate clinical probability of ACS. The HEART pathway (combining HEART score with CCTA in selected patients) and the PROMISE trial data show CCTA as an alternative first-line strategy to functional testing in stable intermediate-risk chest pain 5 / Solid .

CCTA is particularly useful for: ruling out significant obstructive coronary artery disease in low-to-intermediate risk patients who are ruled out by troponin protocol but require anatomical clarification; characterizing plaque morphology (detecting high-risk plaque features like spotty calcification, positive remodeling, and low-attenuation plaque); and planning for invasive angiography by identifying dominant coronary anatomy before catheterization.

CCTA cannot be used in patients with irregular heart rates (atrial fibrillation), very high heart rates, or severe coronary calcification (calcium score above 400 Agatston units, which obscures vessel lumen assessment). It requires contrast administration and delivers radiation (dose approximately 2 to 5 mSv with current scanners and dose-reduction protocols).

Evidence Extended

FRISC-II: Establishing the Invasive Strategy

FRISC-II (1999) was a pivotal trial in NSTEMI management. It randomized 2,457 patients with NSTEMI or unstable angina to an early invasive strategy (coronary angiography within 7 days with revascularization as appropriate) versus a non-invasive strategy (medical therapy with crossover to angiography for refractory symptoms). At 6 months, the invasive strategy reduced the composite of death or MI from 12.1 percent to 9.4 percent (p=0.031) and significantly reduced the need for hospitalization for refractory angina 5 / Solid 07252-1). This trial established the superiority of a routine early invasive strategy over initial conservative management in high-risk NSTEMI patients.

TACTICS-TIMI 18: Confirming the Early Invasive Benefit

TACTICS-TIMI 18 randomized 2,220 patients with ACS to early invasive strategy (angiography within 4 to 48 hours) versus conservative management (angiography for recurrent ischemia or abnormal stress test). The invasive arm significantly reduced the primary endpoint (death, MI, or rehospitalization for ACS at 6 months: 15.9 percent versus 19.4 percent; OR 0.78; p=0.025). The benefit was concentrated in high-risk patients: those with raised troponin, ST depression, or TIMI risk score above 3 5 / Solid .

The TIMI risk score for NSTEMI/UA (Antman 2000) assigns one point each for: age above 65, at least three CAD risk factors, prior coronary stenosis above 50 percent, ST deviation on ECG, at least two anginal episodes in the prior 24 hours, aspirin use in the prior 7 days, and raised serum cardiac markers. Scores of 5 to 7 confer 26 to 41 percent rate of adverse events at 14 days. The score is the most widely validated risk stratification tool for ACS.

TIMACS: Timing of the Invasive Strategy

The TIMACS trial addressed an unresolved question from FRISC-II and TACTICS-TIMI 18: how early should “early invasive” be? TIMACS randomized 3,031 NSTEMI/UA patients to early intervention (angiography within 24 hours) versus delayed intervention (angiography after 36 hours or later). In the overall population, early intervention reduced refractory ischemia (3.9 percent versus 5.4 percent; p=0.003) but did not significantly reduce death or MI in the intention-to-treat analysis. In the pre-specified highest-risk subgroup (GRACE risk score above 140), early intervention significantly reduced death, MI, or stroke (13.9 percent versus 21.0 percent; HR 0.65; p=0.006) 5 / Solid .

TIMACS established that the urgency of catheterization in NSTEMI is risk-stratified: very high-risk patients (GRACE score above 140, refractory ischemia, hemodynamic instability, life-threatening arrhythmia) benefit from immediate invasive strategy (within 2 hours). High-risk patients (GRACE 109-140) benefit from early invasive within 24 hours. Low-to-intermediate risk patients can be managed with delayed invasive strategy within 72 hours or with selective invasive approach after non-invasive testing.

ACUITY: Anticoagulation in NSTEMI

The ACUITY trial randomized 13,819 patients with moderate-to-high-risk ACS (NSTEMI majority) to three anticoagulation strategies: UFH/enoxaparin plus GPIIb/IIIa inhibitor versus bivalirudin plus GPIIb/IIIa inhibitor versus bivalirudin monotherapy. Bivalirudin monotherapy was non-inferior for ischemic outcomes and significantly reduced major bleeding compared to UFH/enoxaparin plus GPIIb/IIIa inhibitor (3.0 percent versus 5.7 percent; p<0.001) 5 / Solid . The net clinical benefit favored bivalirudin monotherapy, primarily driven by the dramatic bleeding reduction.

ACUITY changed the anticoagulation standard for invasive ACS management: bivalirudin as a monotherapy strategy reduces bleeding without increasing ischemic risk, which is a net benefit because major bleeding in ACS independently predicts mortality.

Antiplatelet Escalation: PLATO and TRITON-TIMI 38

The superiority of ticagrelor (PLATO) and prasugrel (TRITON-TIMI 38) over clopidogrel in ACS was established in large RCTs. In the NSTEMI context:

PLATO: Ticagrelor 90 mg twice daily versus clopidogrel 75 mg daily in 18,624 ACS patients. Ticagrelor reduced the primary endpoint (cardiovascular death, MI, or stroke) from 11.7 percent to 9.8 percent at 12 months (HR 0.84; p<0.001), with no significant increase in overall major bleeding, though non-CABG-related bleeding was higher 5 / Solid . Notably, ticagrelor cannot be used in patients requiring CABG within 5 days (washout required to reduce surgical bleeding).

TRITON-TIMI 38: Prasugrel versus clopidogrel in PCI-treated ACS patients. Prasugrel reduced MACE (9.9 percent versus 12.1 percent; HR 0.81; p<0.001) but significantly increased bleeding, including fatal bleeding and intracranial hemorrhage, particularly in patients aged above 75, those with prior stroke/TIA (absolute contraindication), and those weighing below 60 kg 5 / Solid .

Current practice: ticagrelor is the preferred P2Y12 inhibitor in NSTEMI-ACS for most patients; prasugrel is an alternative particularly in patients who have received PCI where platelet inhibition depth is critical and there are no bleeding risk factors; clopidogrel is reserved for patients who cannot tolerate ticagrelor or prasugrel.

Patient Experience Extended

The Uncertainty of NSTEMI

Patients with NSTEMI experience a diagnostic and prognostic uncertainty that differs from STEMI. In STEMI, the diagnosis is immediate and the action is definitive. In NSTEMI, the patient may wait hours before the troponin elevation confirms the diagnosis, and even after diagnosis, the urgency of intervention is tiered by risk score. A patient who has been told they “may be having a heart attack” and then spends 18 to 24 hours waiting for the catheterization laboratory to be available experiences a protracted uncertainty that is psychologically demanding.

Clear communication about the timeline is essential. Telling a patient “we are waiting for more blood tests” without explaining why and what the results will determine leaves the patient in an anxiety vacuum. The explanation: “Your first blood test shows a small amount of heart muscle protein in the blood, which can mean the heart muscle is under stress. We will check it again in one hour to see if it is rising. If it rises, that confirms we need to look at your heart arteries tomorrow morning. If it stays the same, it may mean your heart is not in immediate danger and we can discharge you tonight with close follow-up.”

The difference between these two communications is the difference between an anxious patient who calls the nurse every 30 minutes and a patient who understands what is happening and can cooperate with the monitoring plan.

The Post-NSTEMI Functional Assessment

Not every NSTEMI patient requires immediate invasive strategy. Those triaged to a conservative approach (low-to-intermediate GRACE score, no refractory symptoms, normal hemodynamics) will undergo functional ischemia testing before or instead of invasive catheterization.

The standard functional tests in post-NSTEMI stable patients:

• Exercise treadmill test (ETT): Appropriate for patients with a normal resting ECG and ability to exercise. A positive ETT (ST depression of 1 mm or more, exercise-induced hypotension, limiting angina) warrants invasive evaluation. A negative ETT (adequate heart rate achieved, no ST changes, no symptoms) confers low short-term risk.
• Nuclear stress test (myocardial perfusion imaging): Used when the resting ECG is abnormal (LBBB, LVH, digitalis effect) or when the patient cannot exercise adequately. Superior sensitivity and specificity compared to ETT; adds information about perfusion territory.
• Stress echocardiography: Wall motion assessment at peak stress; equivalent to nuclear testing in experienced labs with the advantage of no radiation.
• CCTA: Provides anatomical detail; particularly useful in low-to-intermediate risk patients where a negative CCTA essentially excludes significant obstructive CAD.

Decisions Extended

The High-Bleeding-Risk Patient with NSTEMI

A patient presenting with NSTEMI who recently had major surgery, who has active gastrointestinal bleeding, who is on therapeutic anticoagulation for a mechanical heart valve, or who has had recent intracranial hemorrhage creates one of the most difficult management dilemmas in cardiology. The standard NSTEMI protocol (anticoagulation, dual antiplatelet therapy, early catheterization) must be modified without abandoning the patient to untreated coronary disease.

The GRACE score and TIMI score quantify ischemic risk. The HAS-BLED and PRECISE-DAPT scores quantify bleeding risk. When both scores are high, the decision requires individualized clinical judgment weighing the competing risks.

Specific modifications for high-bleeding-risk NSTEMI:

• Use bivalirudin over UFH for anticoagulation (lower bleeding risk)
• Use P2Y12 inhibitor with lower bleeding risk: ticagrelor over prasugrel; clopidogrel if ticagrelor’s non-CABG bleeding is a concern
• Shorten dual antiplatelet therapy duration after PCI: 1 to 3 months if DES is used with high bleeding risk, then aspirin monotherapy (supported by STOPDAPT-2 and MASTER DAPT trials)
• Use radial access for catheterization (lower access-site bleeding than femoral)
• Perform catheterization early to definitively characterize anatomy, allowing targeted antiplatelet decisions based on coronary anatomy

Conservative Versus Invasive: When Medical Therapy Is the Right Answer

The cumulative evidence from FRISC-II, TACTICS, TIMACS, ICTUS, and RITA-3 trials, synthesized in multiple meta-analyses, shows that the invasive strategy provides greatest absolute benefit in high-risk NSTEMI patients and minimal to no benefit in low-risk patients.

The ICTUS trial (2005) enrolled patients with NSTEMI and positive troponin and found no significant difference in 1-year outcomes between early invasive and selective invasive strategies, challenging the universality of the early invasive approach 5 / Solid . The divergence from FRISC-II and TACTICS is explained by differences in patient population risk (ICTUS enrolled lower-GRACE-score patients) and differences in the medical therapy used in the conservative arm (ICTUS patients received more aggressive antithrombotic therapy in the conservative arm than FRISC-II controls).

The practical message: the early invasive strategy produces its greatest benefit in patients with GRACE score above 140, positive troponin, ST depression, prior coronary artery disease, or hemodynamic instability. Low-risk patients (GRACE below 109, no ST changes, no hemodynamic compromise, negative troponin at 1 to 2 hours) can be safely managed with medical therapy, stress testing, and elective or selective invasive evaluation, with outcomes equivalent to the routine invasive approach.

This risk-stratified approach is particularly important for elderly patients with multiple comorbidities, for whom the procedural risk of catheterization and PCI may outweigh the marginal benefit of routine revascularization. A 90-year-old with frailty, dementia, and NSTEMI may be best served by guideline-directed medical therapy, symptom management, and a goals-of-care conversation rather than an invasive strategy.

Post-NSTEMI Secondary Prevention: The Evidence Hierarchy

After NSTEMI, the secondary prevention regimen follows an evidence-based hierarchy:

High-intensity statin: rosuvastatin 40 mg or atorvastatin 40 to 80 mg. Target LDL-C below 55 mg/dL (ESC) or below 70 mg/dL (ACC/AHA) for very high-risk patients. Add ezetimibe if LDL-C above target on maximum statin. Consider PCSK9 inhibitor (evolocumab or alirocumab) if LDL-C remains above target on dual lipid-lowering therapy.

ACE inhibitor or ARB: Indicated for all NSTEMI patients with LVEF below 40 percent, diabetes, hypertension, or chronic kidney disease. Reduces adverse LV remodeling and mortality. Start within 24 hours if hemodynamically tolerated.

Beta-blocker: Indicated for all NSTEMI patients with LVEF below 40 percent; recommended for most NSTEMI patients as secondary prevention. Continue for at least 3 years; indefinitely if LVEF remains reduced.

Aldosterone antagonist: Indicated for NSTEMI patients with LVEF below 40 percent plus either diabetes or clinical heart failure, in the absence of significant renal dysfunction or hyperkalemia (EPHESUS trial; 10.1056/NEJMoa030207).

Dual antiplatelet therapy: Aspirin plus P2Y12 inhibitor (ticagrelor preferred) for 12 months in all NSTEMI patients without high bleeding risk. Extended DAPT beyond 12 months (ticagrelor 60 mg twice daily: PEGASUS-TIMI 54 trial) in selected high ischemic risk, low bleeding risk patients.

Blood pressure: Target below 130/80 mmHg in most post-NSTEMI patients.

Glucose management: Target HbA1c below 7 to 7.5 percent in diabetic patients; GLP-1 receptor agonists or SGLT2 inhibitors have independent MACE benefit in post-MI diabetic patients beyond glucose lowering.

The Patient Experience Extended

The NSTEMI Patient Who Is Not in Pain

A significant subset of NSTEMI patients present without classic ischemic chest pain. These presentations include:

Dyspnea as an anginal equivalent: The sensation of chest pressure or pain is replaced by shortness of breath, particularly in elderly patients, women, and diabetic patients with autonomic neuropathy. A 72-year-old woman who presents with progressive dyspnea over 2 days and is found to have ST depression in V4-V6 and an raised troponin is having an NSTEMI. The absence of chest pain does not make the diagnosis less valid or the urgency less real.

Syncope: Transient loss of consciousness from the hemodynamic consequence of a large territory NSTEMI (massive mitral regurgitation from papillary muscle ischemia, complete heart block from RCA territory ischemia) or from the arrhythmic consequence.

Nausea, diaphoresis, and vague malaise: These “autonomic” symptoms (mediated by vagal activation from the ischemic myocardium) can be the dominant presentation, particularly in inferior NSTEMI.

Atypical pain: Jaw pain, left arm pain without chest pain, interscapular back pain (posterior NSTEMI), and epigastric pain (inferior NSTEMI that is misdiagnosed as gastrointestinal disease at initial presentation).

The physician who limits the NSTEMI diagnostic workup to patients complaining of classic “crushing chest pressure radiating to the left arm” will miss a substantial proportion of NSTEMI cases. The ECG and troponin belong in the workup of any patient with unexplained dyspnea, syncope, diaphoresis, or upper abdominal discomfort in an appropriate risk context.

Medication Reconciliation After NSTEMI

The medication regimen after NSTEMI is complex. A patient who previously took no cardiac medications now leaves the hospital on 5 to 7 medications. The risk of medication error, adverse drug interaction, and non-adherence is highest in this transition period.

Specific medication reconciliation priorities at discharge:

1. Confirm aspirin dose: The evidence base for aspirin in post-ACS secondary prevention is dose-dependent. Low-dose aspirin (75 to 100 mg) is as effective as higher doses for MACE prevention and causes less GI bleeding. Many patients are inappropriately discharged on 325 mg aspirin without a specific indication for the higher dose.

2. Confirm P2Y12 inhibitor selection and duration: The patient must understand: do not stop ticagrelor or prasugrel before talking to their cardiologist, even if told to by a dentist or surgeon. Premature cessation is the leading cause of drug-eluting stent thrombosis.

3. Statin discontinuation myths: Patients who have heard that statins cause muscle damage or liver disease and stop their statin after discharge are at significantly higher recurrence risk. Proactively addressing statin myths and verifying that the patient understands the evidence base for statin use improves adherence.

4. ACE inhibitor cough: ACE inhibitor-related dry cough (incidence approximately 10 to 15 percent) is a common reason for medication discontinuation. Patients who develop cough should be switched to an ARB (not the beta-blocker, not the statin) and told explicitly that the switch is to avoid the cough, not because the ACE inhibitor was causing harm.

Decisions Extended

IVUS and OCT Guidance in Complex NSTEMI PCI

Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are catheter-based imaging tools that provide cross-sectional views of the coronary artery lumen and wall at much higher resolution than conventional angiography.

IVUS uses ultrasound (40 to 60 MHz frequency, resolution approximately 100 to 150 micrometers) to show plaque composition, vessel reference diameter, stent expansion, and stent apposition. The COURAGE IVUS substudy and FAME-3 trial provided IVUS-guided PCI data showing better expansion and fewer events versus angiography-guided PCI 4 / Promising .

OCT uses infrared light (wavelength 1,300 nm, resolution approximately 10 to 20 micrometers (10-fold better than IVUS)) to identify plaque features (fibrous cap thickness, lipid arc, calcification) and post-stenting results (stent expansion, edge dissection, tissue prolapse). OCT can identify SCAD with high sensitivity and characterize the mechanism of NSTEMI (plaque rupture versus plaque erosion versus SCAD) in ways that guide subsequent management.

The ILUMIEN III trial showed OCT-guided stenting resulted in better minimum stent area than IVUS-guided or angiography-guided PCI 5 / Solid 31922-5). ILUMIEN IV demonstrated better clinical outcomes with OCT guidance versus angiography guidance in complex PCI 5 / Solid .

In the NSTEMI context, OCT guidance at the time of PCI provides three benefits: confirms the mechanism of the culprit lesion, improves stent sizing and landing zone to avoid edge dissection and incomplete coverage of the plaque, and verifies post-stenting results that predict stent thrombosis risk.

Cardiac Magnetic Resonance After NSTEMI: The Underused Tool

Cardiac MRI after NSTEMI provides information that echocardiography cannot: precise infarct size measurement (percentage of LV mass with LGE), microvascular obstruction (no-reflow area within the infarct zone, which is a stronger predictor of adverse remodeling than infarct size alone), myocardial edema extent (area at risk minus the infarct = salvaged myocardium), and LV thrombus detection (5-fold more sensitive than echocardiography).

In clinical practice, CMR after NSTEMI is performed in selected scenarios where echocardiographic data are insufficient, where arrhythmic risk assessment requires precise scar quantification, or where LV thrombus is suspected on echocardiography but not confirmed. The full clinical adoption of post-MI CMR is limited by scanner availability, cost, and the fact that most NSTEMI management decisions can be made based on clinical, ECG, and echocardiographic data.

The scenario where CMR adds most value after NSTEMI: a patient with new-onset HFrEF after NSTEMI where the severity of LV dysfunction seems disproportionate to the culprit lesion territory, raising the possibility of concomitant myocarditis, stress cardiomyopathy overlapping with the NSTEMI, or underappreciated prior infarction. CMR characterizes the infarct pattern, identifies non-ischemic LGE, and guides the management plan for the LV dysfunction.

NSTEMI in the Elderly: A Distinct Population

Patients above age 80 account for a significant and growing proportion of NSTEMI presentations, yet they are systematically underrepresented in the major NSTEMI trials. The TACTICS-TIMI 18, FRISC-II, TIMACS, and ACUITY trials all had mean ages in the 60s; their results are not automatically applicable to an 84-year-old with frailty, multiple comorbidities, and limited life expectancy.

Several considerations specific to elderly NSTEMI management:

Bleeding risk is dramatically higher. Elderly patients (especially women above 75) have significantly higher rates of major bleeding from anticoagulation and dual antiplatelet therapy. The ACUITY and CRUSADE bleeding risk scores are calibrated for this population and should be applied.

Renal function determines drug dosing. Most antithrombotic agents and P2Y12 inhibitors require dose adjustment for eGFR below 30 mL/min. Renal failure is far more common in elderly NSTEMI patients. Prasugrel is contraindicated in prior stroke and in patients above 75 with low body weight because of excess bleeding risk.

Frailty predicts poor outcomes from intervention. Clinical frailty scales (e.g., Rockwood Clinical Frailty Scale) predict 30-day and 1-year mortality after NSTEMI independent of age and comorbidities. A frail elderly patient with NSTEMI may have outcomes with conservative medical management that are comparable to or better than outcomes with invasive strategy, accounting for the procedural risk, contrast nephropathy risk, and post-procedural delirium risk in this population.

Goals of care conversations are not optional. An 88-year-old patient with moderate dementia, heart failure, and NSTEMI deserves an explicit conversation with family members about whether the goals of care are consistent with invasive cardiac intervention, hospital-based management, or comfort-focused care. This conversation should happen early in the hospitalization, not after the patient has been sent to the catheterization laboratory.

Risk-Stratified Management and Long-Term Outcomes

9.1 The GRACE Score in Daily Practice

The GRACE (Global Registry of Acute Coronary Events) risk score is the most validated tool for predicting in-hospital and six-month mortality in NSTEMI 5 / Solid . It incorporates eight variables: age, heart rate, systolic BP, creatinine, Killip class, cardiac arrest at presentation, ST-segment deviation, and raised cardiac biomarkers. The output is a probability estimate for death at discharge and death at six months.

The clinical value of the GRACE score is not that it replaces clinical judgment. It is that it quantifies risk in a reproducible way that drives the timing of coronary angiography. A GRACE score above 140 defines high-risk NSTEMI: coronary angiography within 24 hours of presentation is the Class I recommendation per ESC guidelines 5 / Solid . A GRACE score of 109 to 140 defines intermediate risk: angiography within 72 hours. A score below 109 defines lower risk: angiography can be performed within 72 hours or after ischemia-guided risk stratification with stress testing.

The TIMACS trial was the RCT that validated early versus delayed invasive strategy in NSTEMI 5 / Solid . In 3,031 patients, early invasive strategy (angiography within 24 hours) compared to delayed (within 36 to 48 hours) produced a significant reduction in the composite of death, MI, or stroke at six months in the high-risk subgroup (GRACE score >140, HR 0.65, 95% CI 0.48-0.89). In the lower-risk subgroup, no significant difference was observed. The lesson: the right management for NSTEMI depends on risk stratification, not on a single protocol applied uniformly.

9.2 MINOCA: The Diagnosis That Changes Management

Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) accounts for approximately 6 to 8 percent of all MI presentations 5 / Solid . In women under 60, the prevalence is higher: up to 10 to 15 percent in some registry series. The diagnostic criteria are: clinical presentation consistent with MI (symptoms, ECG changes, troponin rise), coronary angiography showing no obstructive disease (no stenosis greater than 50 percent in any major epicardial artery), and no alternative diagnosis explaining the presentation (e.g., myocarditis, Takotsubo).

MINOCA is not a single disease. It is a clinical syndrome with multiple mechanisms:

1. Plaque disruption without significant stenosis: Plaque rupture or erosion in a non-flow-limiting plaque causes thrombosis and distal embolization without leaving a visible obstruction on angiography.
2. Coronary vasospasm: Prinzmetal variant angina pattern; provocation testing with acetylcholine or ergonovine can unmask this mechanism.
3. Spontaneous coronary artery dissection (SCAD): More common in young women; intramural hematoma or intimal tear separates the coronary layers without producing a traditional plaque. Optical coherence tomography (OCT) during angiography can identify SCAD that is invisible on standard angiographic views 4 / Promising .
4. Microvascular dysfunction: Impaired vasodilator response in small coronary vessels, measurable by coronary flow reserve (CFR) and index of microvascular resistance (IMR) at the time of catheterization.
5. Type 2 MI: Supply-demand mismatch from tachyarrhythmia, anemia, hypotension, or respiratory failure; the coronaries are not the primary problem.

The management of MINOCA is mechanism-specific. Vasospasm is treated with calcium channel blockers; antiplatelet therapy has no role in pure vasospasm. SCAD is managed with conservative therapy and avoidance of stenting (which can extend the dissection) in most cases. Microvascular dysfunction is treated with ACE inhibitors and statins based on observational data 3 / Early . Applying DAPT to all MINOCA patients indiscriminately is both incorrect and potentially harmful.

9.3 NSTEMI in the Elderly: A Distinct Population

Patients over 80 years represent a growing proportion of NSTEMI admissions. In the United States, adults 75 and older account for more than 35 percent of all MI hospitalizations 5 / Solid . Their presentation is frequently atypical: dyspnea rather than chest pain, delirium rather than diaphoresis, decline in functional status rather than acute distress. The troponin elevation may be modest because baseline troponin levels are higher in elderly patients due to renal impairment and left ventricular hypertrophy.

The benefit of invasive strategy in elderly NSTEMI patients is real but attenuated by procedural risk. The After Eighty trial randomized 457 patients 80 years and older with NSTEMI or unstable angina to invasive versus conservative strategy 5 / Solid 01166-7). At 16-month follow-up, the invasive group had significantly lower rates of the primary endpoint (MI, urgent revascularization, stroke, or death): 41 percent versus 61 percent (OR 0.53, 95% CI 0.41-0.69). Bleeding complications were similar. This trial confirmed that age alone is not a reason to withhold angiography.

However, frailty is. Patients who are frail by validated assessment (Clinical Frailty Scale score 5 or above, or similar) have higher periprocedural mortality, longer recovery times, and less functional benefit from revascularization. The decision framework in very elderly NSTEMI patients should incorporate frailty assessment, goals of care discussion, and shared decision-making with the patient and family before committing to angiography.

9.4 Post-NSTEMI Discharge Planning: The Adherence Problem

The 30-day readmission rate after NSTEMI is approximately 11 to 14 percent in large U.S. database analyses 5 / Solid . A significant proportion of readmissions are not driven by new coronary events. They are driven by: medication non-adherence, heart failure exacerbation from incomplete prescribing, bleeding complications from antiplatelet therapy without proton pump inhibitor coverage, uncontrolled diabetes, and unrecognized depression.

Medication costs are a concrete driver of non-adherence. After NSTEMI, a patient on full secondary prevention therapy may face out-of-pocket costs for: ticagrelor ($350-450 per month without copay assistance), a PCSK9 inhibitor ($500-700 per month without assistance), a second generation DES-related follow-up echocardiogram, and cardiac rehabilitation copays. Many patients rationally choose to fill only the medications they can afford and do not tell their physician.

The standard prescription at discharge should include: an explicit cost conversation; pharmacy benefit check for 90-day supply discounts; referral to manufacturer copay assistance programs (AstraZeneca copay assistance for Brilinta; Amgen EnrollReady for Repatha); and a plan for what to do if the patient cannot afford ticagrelor (clopidogrel 75 mg daily is the fallback; it is inferior to ticagrelor in PLATO but is far better than no antiplatelet therapy).

A structured cardiovascular assessment flags cost barriers prospectively. A cardiologist-led preventive program provides a dedicated medication reconciliation and affordability review at 30 days post-discharge. These are not luxury services: they address the leading modifiable cause of preventable MI readmission.

9.5 The Six-Month Reassessment: What Must Happen

At six months post-NSTEMI, the following assessments are non-negotiable:

1. Repeat echocardiogram if initial EF was below 50 percent. Confirm recovery or document persistent dysfunction for GDMT improvement decisions.
2. Lipid panel. Confirm LDL-C below 70 mg/dL (below 55 mg/dL for very high-risk patients). Add ezetimibe or PCSK9 inhibitor if target not reached.
3. HbA1c. Diabetes and hyperglycemia are major drivers of recurrent events. GLP-1 agonists (liraglutide, semaglutide) have proven cardiovascular benefit in diabetic patients with established ASCVD 5 / Solid .
4. Creatinine and potassium. ACE inhibitor and aldosterone antagonist dosing may require adjustment with renal function changes.
5. DAPT duration decision. The default twelve-month DAPT duration can be extended to 24 to 36 months for very high-risk patients (prior MI, diabetes, complex PCI) based on the DAPT trial 5 / Solid and PEGASUS-TIMI 54 trial 5 / Solid . It can be shortened to six months for high-bleeding-risk patients based on TWILIGHT 5 / Solid and MASTER DAPT 5 / Solid .

Dr. Job Mogire, MD FACP FACC. Carle Foundation Hospital; Carle Illinois College of Medicine. Stop Dying Early.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.